New AMA CPT Category III Code Supports Expanded Access to Non-Opioid BioWavePENS Therapy for Patients Living with Pain 

Norwalk, CT — June 3, 2026—Patients living with chronic nociceptive and neuropathic pain may soon benefit from greater access to physician-delivered, non-opioid treatment options following approval of a new American Medical Association (AMA), Current Procedural Terminology (CPT) Category III code for BioWave’s microneedle-based Percutaneous Electrical Neuromodulation (PENS) procedure.

The new code establishes a dedicated mechanism for tracking utilization of this emerging treatment approach and represents an important step toward data collection, consistent reimbursement, and broader clinical adoption.

The approval of the code which is for percutaneous application of high frequency neuromodulation signals using microneedle electrode arrays for the treatment of nociceptive or neuropathic pain,represents an important milestone for BioWave and establishes a dedicated procedural coding pathway for the company’s percutaneous electrical neuromodulation, or PENS, technology platform. BioWave’s PENS procedure uses microneedle electrode arrays to deliver high frequency neuromodulation signals percutaneously for the treatment of nociceptive or neuropathic pain. The procedure includes electrode placement and patient training and is designed for use by trained healthcare providers in appropriate clinical settings.

“Pain remains one of the most challenging conditions facing patients and healthcare providers today,” said Brad Siff, President of BioWave Corporation. “This new CPT code is important because it helps create a clearer pathway for physicians to utilize, track and get paid for an innovative, non-opioid treatment option for patients who are often searching for alternatives to medications, injections, nerve ablation, or surgery. Ultimately, this milestone is about expanding access to care and continuing to build the evidence needed to support better outcomes for patients.”

AMA CPT Category III codes are temporary codes used to identify and track emerging medical technologies, services, and procedures. The creation of a Category III code allows utilization of the procedure to be reported more specifically and supports the collection of clinical and claims-related data as adoption expands.

“This dedicated code will help BioWave and our clinical partners better support physician education, patient access discussions, utilization tracking, and future reimbursement development,” Siff continued.

BioWave expects the new code to support expanded commercial activity across the United States, including physician training, customer education, clinical workflow development, and engagement with healthcare stakeholders interested in non-opioid, non-destructive approaches to pain treatment.

The company plans to work closely with physicians, clinics, health systems, government healthcare facilities, distributors, vendors, and other partners to support the responsible rollout of BioWavePENS in appropriate clinical settings. BioWave will also continue to develop clinical evidence, real-world outcomes data, and health economic information to support a broader understanding of the technology and its role in pain management.

“Pain remains one of the most significant clinical challenges in healthcare,” said Rob Wolter, CEO of BioWave Corporation. “BioWave is committed to helping providers address nociceptive and neuropathic pain with innovative neuromodulation technologies designed to deliver targeted peripheral nerve stimulation without drugs, surgery, nerve destruction, or implanted hardware.”

This approval strengthens BioWave’s position in the pain management market and provides an important platform for future growth of its PENS business.

About BioWave Corporation
BioWave Corporation is a medical device company focused on high frequency peripheral neuromodulation technologies for the treatment of severe pain. BioWave develops and commercializes noninvasive and percutaneous neuromodulation solutions used by healthcare providers and patients across a range of pain conditions, including nociceptive, neuropathic, musculoskeletal, post-operative, and other difficult-to-treat pain states.

Important Information Regarding Reimbursement

AMA CPT Category III codes are intended to facilitate reporting and tracking of emerging medical procedures and technologies. Approval of an AMA CPT Category III code does not guarantee coverage, reimbursement, or payment by Medicare, Medicaid, commercial insurers, or other payors. Coverage and payment decisions are determined independently by individual payors and may vary based on clinical circumstances and applicable policies.